Source comparison
Comparison: CJC-1295 vs Other Recovery-Targeted Peptides
| Peptide | Mechanism of Action | Half-Life | IGF-1 Response Duration | Primary Recovery Marker | Research Stage | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 (with DAC) | GHRH analog; stimulates endogenous GH secretion via pituitary receptor binding | 6–
This comparison does not assign a generated winner or score.
- | Peptide | Mechanism of Action | Half-Life | IGF-1 Response Duration | Primary Recovery Marker | Research Stage | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 (with DAC) | GHRH analog; stimulates endogenous GH secretion via pituitary receptor binding | 6–8 days | 6–9 days (sustained elevation) | Nitrogen retention, reduced CK, faster strength return | Phase II clinical trials completed; ongoing research applications | Longest-acting GH secretagogue with sustained IGF-1 elevation. Ideal for multi-day recovery windows || Ipamorelin | Ghrelin mimetic; stimulates GH release via ghrelin receptor (GHSR-1a) | 2 hours | 4–6 hours (pulsatile) | Transient GH spike, minimal IGF-1 change | Preclinical and early human trials | Short half-life limits recovery impact unless dosed multiple times daily; often stacked with CJC-1295 || BPC-157 | Gastric peptide analog; promotes angiogenesis and collagen synthesis | 4–6 hours (estimated) | No direct IGF-1 effect | Tendon healing, gut repair, localize